AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
As of today, AbbVie(ABBV) shares are valued at $262.10. The company's market cap stands at 463.16B, with a P/E ratio of 74.37 and a dividend yield of 2.60%.
During the trading session on 2026-09-16, AbbVie(ABBV) shares reached a daily high of $264.00 and a low of $260.98. At a current price of $262.10, the stock is +0.4% higher than the low and still -0.7% under the high.
Trading activity shows a volume of 1.53M, compared to an average daily volume of 4.35M.
The stock's 52-week range extends from a low of $190.75 to a high of $267.47.
The stock's 52-week range extends from a low of $190.75 to a high of $267.47.
ABBV News
AbbVie ABBV has significantly transformed its neuroscience portfolio over the years, evolving it from a relatively concentrated business initially anchored by V...
Key Points AbbVie has a fantastic dividend track record. The company's rock-solid business should help maintain its dividend growth streak for a long time. B...
Key Points Ken Griffin's Citadel increased its AbbVie stake by over 500% in the second quarter of 2026. AbbVie isn't cheap, but it has a strong drug portfolio...
Analyst ratings
75%
of 32 ratingsMore ABBV News
Key Points AbbVie generates billions in annual free cash flow and continues to expand its market share in immunology treatments. CRISPR Therapeutics is a lead...
Investing Do the Math: Tax Man Goes Away When You Own These Dividend Stocks in a Roth IRA A Roth IRA turns every dividend into a tax shield: qualified distribut...
Abbvie (ABBV) announced an update on their ongoing clinical study. The AbbVie Inc. (ABBV) ECLIPSE study, officially titled “Randomized, Double-blind, Placebo-C...
AbbVie Inc. (NYSE:ABBV) shares are edging higher Friday morning following Thursday’s announcement of positive Phase 3 trial results for its menstrual migraine t...
Ipsen is debating on building a production site in the U.S., with plans the next big plant built will manufacture either its Dysport drug, a rival to AbbVie’s (...
AbbVie Inc. (NYSE:ABBV) on Thursday released topline results from its Phase 3 LUNA clinical trial. The study assessed atogepant, an oral calcitonin gene-relate...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie is reporting new data from an observational eye study in adults with diabetic macular...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.